Cargando…

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)

Detalles Bibliográficos
Autores principales:	Verburg-Baltussen, E. J., Stewart, A., Liu, F. F., Parker, C., Peterse, E. F., Treur, M., Malcolm, B., Klijn, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430721/ http://dx.doi.org/10.1097/01.HS9.0000849832.54477.ed

Ejemplares similares

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
por: Trando, Aaron, et al.
Publicado: (2023)

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review
por: Weinstein, Bayarmagnai, et al.
Publicado: (2021)

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022)

P1174: THE COMBINATION OF QUALITATIVE AND QUANTITATIVE METABOLIC PARAMETERS PREDICTS PROGRESSION-FREE SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS (LBCL) TREATED WITH ANTI-CD19 CAR-T CELLS.
por: Dodero, A., et al.
Publicado: (2022)

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
por: Perez, Ariel, et al.
Publicado: (2022)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Lunacy, Law, and Conscience, 1744-1845
por: Ratcliffe, T. A.
Publicado: (1955)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

The author of the Pharmacopoeia Reformata 1744 (William Lewis).
por: Earles, M
Publicado: (1976)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Pulse arrival-time glitches in GRO J1744-28
por: Stark, M J, et al.
Publicado: (1996)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

John Coakley Lettsome (1744-1815) Philanthropologist and physician
por: Breathnach, Caoimhghín S
Publicado: (2015)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

P1204: TREATMENT PATTERNS AND REAL-WORLD OUTCOMES IN PATIENTS (PT) WITH LARGE B-CELL LYMPHOMA (LBCL) WHO RECEIVED SECOND-LINE (2L) THERAPY
por: Lunning, M., et al.
Publicado: (2022)

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
por: Munoz, Javier, et al.
Publicado: (2023)

La civilisation de la Nouvelle-France, 1713-1744 /
por: Frégault, Guy
Publicado: (1969)

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019)

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
por: Staudt, Ross E, et al.
Publicado: (2022)

Quasi-periodic X-ray brightness oscillations of GRO J1744-28
por: Zhang, W, et al.
Publicado: (1996)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

Los diarios de Gaspar Melchor de Jovellanos (1744-1811)
por: Vogt, Wolfgang, 1945-
Publicado: (1991)

Los diarios de Gaspar Melchor de Jovellanos, 1744-1811
por: Vogt, Wolfgang, 1945-
Publicado: (1991)

Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
por: Rad S. M., Ali Hosseini, et al.
Publicado: (2021)

Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
por: Kanwal, Bushra
Publicado: (2021)

PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
por: Accorsi Buttini, E., et al.
Publicado: (2022)

1744. CMV Infection and Management Among Pediatric Solid-Organ Transplant Recipients
por: Sharova, Anna, et al.
Publicado: (2019)

1744. Next generation sequencing (NGS) optimization of Oral Polio Vaccine samples
por: Carrington, Yuan J, et al.
Publicado: (2023)

Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Aparicio, Cristina, et al.
Publicado: (2021)

T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
por: De Bousser, Elien, et al.
Publicado: (2021)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
por: Kravets, Victoria G, et al.
Publicado: (2017)

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
por: Sridhar, Praveen, et al.
Publicado: (2017)

Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
por: Sutherland, Ashley R., et al.
Publicado: (2020)

Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
por: Brown, Kevin, et al.
Publicado: (2021)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
por: Taneja, Alankrita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_na19pb8mi3se5q6m2n3ie63vse